5 (34)
Pipeline Therapeutics announced that it has raised $80 million in investor financing to develop neuroregenerative therapies for neurological disorders, including those like multiple sclerosis (MS) that are marked by the loss of myelin.
The money will support the research and development of several candidate therapies, with three aimed at promoting and restoring neuronal health.
“We are proud to have this significant support for our mission of developing first- and best-in-class neuroregenerative product candidates for unserved and underserved neurological indications,” Carmine Stengone, president and CEO of Pipeline, said in a press release.
The lead treatment candidate for MS is called PIPE-307, and is designed to help regrow myelin (remyelination), the protective sheath that insulates nerve cell axons against signal loss, much like the coating found around electrical wires.
Early-life Trauma Affects MS Development, Treatment in Mice 4.8 (30)
Childhood trauma can affect disease progression of multiple sclerosis (MS) and treatment in adulthood, a study in mice suggests.
The study shows that mice that experienced early-life trauma were more likely to develop an autoimmune condition and less likely to respond to common treatment with interferon beta.
The study, “
MS is a progressive, multifactorial disease with both genetic and environmental factors contributing to it. Childhood trauma (early-life) trauma emotional neglect or physical abuse, for instance has been associated with higher relapse rates in MS. However, the underlying mechanism through which it alters MS progression remains unknown.